2026 Interim report
Filed with HKEX · Stock code 2162 · · 69 pages · English
2 Definitions 6 Corporate Information 8 Management Discussion and Analysis 26 Supplementary Information 37 Interim Condensed Consolidated Statement of Profit or Loss 38 Interim Condensed Consolidated Statement of Comprehensive Income 39 Interim Condensed Consolidated Statement of Financial Position 41 Interim Condensed Consolidated Statement of Changes in Equity 43 Interim Condensed Consolidated S
Keymed Biosciences, Inc. on 6ix
Earlier from Keymed Biosciences
- Keymed Biosciences Announces 2026 H1 Results and Business Updates
- Keymed Biosciences Announces 2025 Annual Results and Business Updates
- Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
- Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine
- Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
Later from Keymed Biosciences
All Keymed Biosciences news releasesFollow Keymed Biosciences into a list and get an email when it puts out news.
Follow Keymed Biosciences